Systemic anaplastic large cell lymphoma

The Pharmaceutical Benefits Scheme subsidises brentuximab vedotin for eligible patients.

The Pharmaceutical Benefits Scheme subsidises brentuximab vedotin for eligible patients for the treatment of CD 30 positive systemic anaplastic large cell lymphoma.

Authority to provide brentuximab vedotin (Adcetris®) for the treatment of CD 30 positive systemic anaplastic large cell lymphoma is available under Section 100 – Efficient funding of chemotherapy of the National Health Act 1953.

Restriction details

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin.

Initial treatment

All patients starting treatment with brentuximab vedotin must meet all aspects of the initial PBS criteria. Patients will be approved for a maximum of 4 cycles only.

Patients are eligible for a maximum of 12 cycles of continuing treatment provided they do not have progressive disease.

Treatment must not exceed a lifetime total of 16 cycles.

Continuing treatment

For more information on applying to continue treatment for patients who have not experienced disease progression, contact us on the Complex Drugs enquiry line.

Item details

Dose - You must specify on the prescription the dose to be administered in milligrams per infusion. Vial size does not need to be specified. The recommended dose is 1.8mg/kg.

Initial application - Prescriptions should be written for a sufficient dose (@ 1.8mg/kg) of brentuximab. No more than 4 cycles will be authorised.

Continuing application - Prescriptions should be written for a sufficient dose (@ 1.8mg/kg) of brentuximab. No more than 12 cycles will be authorised.

Patient eligibility

Patients must meet the relevant criteria as indicated in the PBS restrictions and be eligible for the Pharmaceutical Benefits Scheme.

Test requirements

All initial applications must include:

  • a copy of the histology report subsequent to the most recently delivered prior treatment with radiation, chemotherapy, biologics, immunotherapy or other agents confirming CD30 positivity of the tumour

Lodging an application

Send all written applications to Complex drugs address on the contact us page.

Further information

For more information contact us on the Complex Drugs enquiry line.

Page last updated: 27 January 2016

This information was printed Monday 5 December 2016 from humanservices.gov.au/health-professionals/enablers/systemic-anaplastic-large-cell-lymphoma It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.